View the list Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products , for additional information including letters of authorization, fact sheets, Dear Health Care Provider letters, and additional information about COVID-19 therapeutics.
The HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to section 564 of the FD&C Act, effective March 27, 2020. The EUAs subsequently issued by FDA are listed in the table on the page: Emergency Use Authorizations for Drugs and Non-Vaccine Biological Products .
View the FDA’s COVID-19 Drugs page to see all products approved to treat COVID-19 without any remaining EUA authorized uses.
Revocation notices for COVID-19 drug and biological product EUAs are available at: Emergency Use Authorization--Archived Information .
Related links:
Information about COVID-19 EUAs for medical devices can be found below and at: Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations for Medical Devices .
March 24, 2023 - The FDA finalized two guidances: Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency and Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19) . The guidances outline the FDA’s general recommendations to transition from certain policies adopted and operations implemented during the COVID-19 pandemic to normal operations, including the FDA’s recommendations for:
The FDA encourages stakeholders to review the two final guidances, attend the webinar noted below, and reach out to the FDA if they have questions. In particular, for manufacturers that are planning to seek marketing authorization for their devices, the FDA recommends beginning work on a marketing submission, including a transition implementation plan, as described in the guidances.
On February 4, 2020 , the Secretary determined pursuant to section 564 of the FD&C Act that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad and that involves a novel (new) coronavirus (nCoV) first detected in Wuhan City, Hubei Province, China in 2019 (2019-nCoV).
On the basis of this determination, the HHS Secretary issued three declarations related to medical devices:
For identification of the applicable declaration for each EUA, please see each EUA letter of authorization and/or the corresponding Federal Register notice.
Please see the page In Vitro Diagnostics EUAs for information about in vitro diagnostics EUAs, including templates.
For current SARS-CoV-2 in vitro diagnostic EUAs, see:
On February 29, 2020, the FDA issued an immediately in effect guidance with policy specific to development of in vitro diagnostic tests during this public health emergency. This guidance was updated on March 16, 2020, May 4, 2020, and May 11, 2020. On September 27, 2022, FDA updated this policy to ensure continued access to tests while encouraging the transition of these important public health tools to traditional premarket review pathways. The updated policy describes the FDA’s intent to review only a small subset of new EUA requests for diagnostic tests and encourages developers of all test types interested in marketing authorization to pursue authorization through the de novo classification or 510(k) clearance pre-market review pathways.
CDC has granted a right of reference to the performance data contained in CDC's EUA (FDA submission number EUA200001) to any entity seeking an FDA EUA for a COVID-19 diagnostic device.
Templates for these EUA submissions are available to help facilitate the preparation, submission, and authorization of an EUA.
For additional information, see Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised) , FAQs on Diagnostic Testing for SARS-CoV-2 , EUA Authorized Serology Test Performance , and CLIA and University Laboratory Testing FAQ (CMS).
For a list of all molecular SARS-CoV-2 diagnostic tests that have been cleared or granted De Novo classification, see devices with product codes QOF and QQX in FDA’s medical devices databases for 510(k) and De Novo. For a list of all antigen SARS-CoV-2 diagnostic tests that have been cleared or granted De Novo classification, see devices with product code QVF in FDA’s medical devices databases for 510(k) and De Novo. For a list of all SARS-CoV-2 serology tests that have been cleared or granted De Novo classification, see devices with product code QVP in FDA’s medical devices databases for 510(k) and De Novo.
Please see the page Personal Protective Equipment EUAs for current EUAs.
For additional information, see Recent Final Medical Device Guidance Documents , and Non-NIOSH Approved Respirator FAQ .
See Revoked EUAs for Non-NIOSH-Approved Disposable Filtering Facepiece Respirators and Decontamination and Bioburden Reduction Systems below for information about June 30, 2021 EUA revocations.
Please see the following pages for EUA templates and additional information about other types of medical device EUAs for COVID-19:
On June 30, 2021, the FDA announced the revocation of the following EUAs:
As of the effective date of the revocations, these devices will no longer be authorized for use by health care personnel in health care settings.
For additional information, please see Update: FDA No Longer Authorizes Use of Non-NIOSH-Approved or Decontaminated Disposable Respirators - Letter to Health Care Personnel and Facilities [ARCHIVED]. Historical information regarding these EUAs can be found on Historical Information about Device Emergency Use Authorizations and Emergency Use Authorization--Archived Information .
back to About EUAs
Mpox vaccine euas.
On November 28, 2022, the World Health Organization announced , and the U.S. government supported , renaming monkeypox disease to mpox. In response to this action by the WHO, federal public health agencies will adopt the mpox name in correspondence with the medical community and American public from this point forward.
Effective August 9, 2022 , pursuant to section 564 of the FD&C Act, the HHS Secretary declared :
Vaccine EUAs subsequently issued by FDA are listed in the table below.
PREP Act declaration: Effective September 28, 2022, the HHS Secretary amended the declaration first issued on October 10, 2008, and amended and republished effective January 1, 2016 for smallpox countermeasures and countermeasures against other orthopoxviruses pursuant to section 319F-3 of the Public Health Service Act to emphasize that the declaration applies to monkeypox virus, to expand the categories of providers authorized to administer vaccines and therapeutics against smallpox (variola virus), monkeypox virus, and other orthopoxviruses in a declared emergency, and to extend the duration of the declaration. About PREP Act declarations
Date of First EUA Issuance | Letter of Authorization (PDF) | Authorized Use | Fact Sheets and Manufacturer Instructions/Package Insert (PDF) | Additional Information and Decision Memoranda (PDF) | Federal Register Notice for EUA |
---|---|---|---|---|---|
August 9, 2022 | (602KB) (August 16, 2022) (133KB) | (343KB) (updated August 16, 2022) (465KB) (Chinese, Simplified) (Korean) (Spanish) (Tagalog) (Vietnamese)(290KB) | (295KB) | (October 7, 2022) |
Effective September 7, 2022, pursuant to section 564 of the FD&C Act, the HHS Secretary declared :
Diagnostic EUAs subsequently issued by FDA are listed in the table on this page: Monkeypox Emergency Use Authorizations for Medical Devices .
Additional information for product developers is available at:
Note that FDA previously cleared real-time polymerase chain reaction (PCR) tests that detect non-variola orthopoxvirus DNA, including the virus that causes mpox. Learn more about these tests: Monkeypox Tests (In Vitro Diagnostic (IVD) Devices) .
Date of First EUA Issuance | Additional Information | Federal Register Notices |
---|---|---|
September 7, 2022 | - Including a list of current medical device EUAs for mpox - Answers to frequently asked questions relating to the development and performance of tests to detect the virus that causes mpox, primarily intended for test developers (September 7, 2022) | (October 7, 2022) (October 27, 2022) (December 30, 2022) (January 11, 2023) (January 31, 2023) (March 10, 2023) (April 17, 2023) |
On October 20, 2022, FDA also published lists of certain laboratories that have notified FDA of their laboratory developed monkeypox diagnostic test ( LDT ), modification to an FDA-cleared or EUA-authorized monkeypox diagnostic test, or laboratory developed monkeypox serology test, as described in Sections IV.A.2, IV.A.3, and IV.C, respectively, of the Policy for Monkeypox Tests to Address the Public Health Emergency . While FDA has not reviewed the laboratory’s validation of the listed tests and has not issued EUAs for these tests, we are providing this information to promote transparency.
For additional information about monkeypox (mpox), see: FDA mpox Response and Monkeypox and Medical Devices .
The tables below provide information on current EUAs:
Ebola virus eua information, freeze dried plasma information, h7n9 influenza eua information, middle east respiratory syndrome coronavirus (mers-cov) eua information, nerve agent eua information, zika virus eua information.
Information about EUAs that are no longer in effect is available on our EUA archive page .
back to top of page
The 2016 FDA Doxycycline Emergency Dispensing Order and CDC Doxycycline Emergency Use Instructions (EUI) together replace the need for the doxycycline mass dispensing EUA (issued on July 21, 2011). Therefore, the doxycycline emergency dispensing order and EUI should be used by stakeholders for anthrax preparedness and response instead of the mass dispensing EUA. The July 21, 2011, doxycycline mass dispensing EUA, and the October 14, 2011, National Postal Model anthrax EUA will be terminated by FDA, and notice of such termination will be published in the Federal Register . For additional information, see Emergency Use Authorization--Archived Information .
back to list of current EUAs
Ebola preparedness and response updates from FDA (all agency activities)
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: 2014 Ebola Virus Emergency Use Authorizations .
Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
---|---|---|---|---|---|---|
EZ1 Real-time RT-PCR Assay | August 5, 2014 (initial issuance) October 10, 2014 (reissuance)
| (PDF, 61 KB) |
| (PDF, 58 KB) (PDF, 59 KB) (PDF, 1.1 MB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
CDC Ebola Virus NP Real-time RT-PCR Assay | October 10, 2014 (initial issuance) March 2, 2015 (reissuance) October 8, 2019 (amended)
| (PDF, 282 KB)
|
| (PDF, 207 KB) (PDF, 149 KB) (PDF, 496 KB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
CDC Ebola Virus VP40 Real-time RT-PCR Assay | October 10, 2014 (initial issuance) March 2, 2015 (reissuance) October 8, 2019 (amended)
| (PDF, 285 KB)
|
| (PDF, 207 KB) (PDF, 149 KB) (PDF, 494 KB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
FilmArray Biothreat-E test | October 25, 2014 November 12, 2019 (amended) | (PDF, 73 KB)
|
| (PDF, 227 KB) (PDF, 191 KB) (PDF, 1.6 MB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
RealStar Ebolavirus RT-PCR Kit 1.0 | November 10, 2014 (initial issuance) November 26, 2014 (reissuance)
| (PDF, 263 KB) |
| (PDF, 81 KB) (PDF, 92 KB) (PDF, 797 KB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
LightMix Ebola Zaire rRT-PCR Test | December 23, 2014 | (PDF, 2.2 MB) |
| (PDF, 59 KB) (PDF, 60 KB) (PDF, 328 KB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
Xpert Ebola Assay | March 23, 2015 June 13, 2023 (amended) | (PDF, 240 KB) (PDF, 171 KB) |
| (PDF, 310 KB) (PDF, 211 KB) (PDF, 625 KB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) | |
DPP Ebola Antigen System (Chembio Diagnostic Systems, Inc.) | November 9, 2018 April 2, 2019 (amended) | (PDF, 103 KB) (PDF, 87 KB) |
| (PDF, 122 KB) (PDF, 119 KB) (PDF, 2 MB) | Diagnostics for Detection of Ebola Virus (August 4, 2014) |
Also see FDA News Release: FDA takes action to support American military personnel by granting an authorization for freeze-dried plasma product to enable broader access while the agency works toward approval of the product (July 10, 2018)
Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
---|---|---|---|---|---|---|
Pathogen-Reduced Leukocyte-Depleted Freeze Dried Plasma (Centre de Transfusion Sanguine des Armées)
| July 9, 2018 (initial issuance) May 8, 2020 (amendment) August 29, 2023 | (PDF, 203 KB) (PDF, 60 KB) (PDF, 133 KB) |
| (PDF, 173 KB) (PDF, 186 KB) | Determination by DoD (June 7, 2018) (July 9, 2018) |
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: 2013 H7N9 Influenza Emergency Use Authorization (Potential Emergency) .
Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheet and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
---|---|---|---|---|---|---|
CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel-Influenza A/H7 (Eurasian Lineage) Assay | April 22, 2013 (initial issuance)
March 27, 2018 (reissuance) | (PDF, 301 KB), re-issued March 27, 2018
|
| (PDF, 46 KB) (PDF, 32 KB) (PDF, 433 KB) | Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013)
| (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
Quidel Lyra Influenza A Subtype H7N9 Assay | February 14, 2014 | (PDF, 57 KB) |
| (PDF, 42 KB) (PDF, 40 KB) | Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013)
| (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
A/H7N9 Influenza Rapid Test | April 25, 2014 |
|
| Diagnostics for Detection of the Avian Influenza A (H7N9) Virus (April 19, 2013)
| (The amendment of the October 10, 2008, declaration as amended June 11, 2009, the December 17, 2008, declaration and February 29, 2012, declaration is effective as of January 1, 2016.) |
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: 2013 Coronavirus Emergency Use Authorization (Potential Emergency) .
Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
---|---|---|---|---|---|---|
CDC Novel Coronavirus 2012 Real-time RT-PCR Assay | June 5, 2013 (initial issuance) June 10, 2014 (reissuance)
| (PDF, 2.2 MB) |
| (PDF, 1.2 MB) (PDF, 743 KB) | Diagnostics for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (May 29, 2013)
|
|
RealStar MERS-CoV RT-PCR Kit U.S. | July 17, 2015 February 12, 2016 (reissuance)
| (PDF, 238 KB) |
| (PDF, 269 KB) (PDF, 241 KB) (PDF, 1.28 MB) (PDF, 285 KB) | Diagnostics for Detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (May 29, 2013)
|
On July 9, 2018, FDA approved (PDF, 49 KB) the 2 mg Atropine Auto-Injector manufactured by Rafa Laboratories, Ltd., for the treatment of poisoning by susceptible organophosphorous nerve agents having cholinesterase activity as well as organophosphorous or carbamate insecticides in adults and pediatric patients weighing over 90 lbs [41 kg] (generally over 10 years of age). For more information about the approved 2 mg Rafa Atropine Auto-Injector, see the product label (PDF, 482 KB). The EUA detailed in the table below is still in effect.
Medical Product | Date of EUA Issuance | Letter of Authorization | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
---|---|---|---|---|---|---|
Atropine Auto-Injector (Rafa Laboratories Ltd.) | April 11, 2017 (initial issuance) May 23, 2017 (amended) January 24, 2018 (amended) March 6, 2018 (amended) May 15, 2018 (amended) | (PDF, 514 KB) (PDF, 28 KB) (PDF, 33 KB) (PDF, 85 KB) (PDF, 42 KB) | | (PDF, 531 KB) (PDF, 675 KB) | (April 11, 2017) | (April 11, 2017) |
Zika virus response updates from FDA
For more information about the diagnostics below, also see Emergency Use Authorizations for Medical Devices: Zika Virus Emergency Use Authorization .
Draft EUA review templates for Zika are available by email request to: [email protected]
Laboratory personnel using Zika diagnostic assays under EUA are encouraged to report performance concerns directly to FDA at [email protected] , in addition to reporting concerns to the manufacturer.
Medical Product | Date of EUA Issuance | Letters | Federal Register Notice for EUA | Fact Sheets and Manufacturer Instructions/Package Insert | EUA Determination and Declaration (Effective Date) | PREP Act Declaration (if applicable) |
---|---|---|---|---|---|---|
CDC Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay
| February 26, 2016 (initial issuance) June 29, 2016 (amended) November 15, 2016 (amended) December 6, 2016 (amended) May 3, 2017 (amended) July 31, 2017 (amended) April 16, 2018 (amended) September 26, 2018 (amended) | (PDF, 155 KB) (PDF, 123 KB) (PDF, 110 KB) (PDF, 113 KB) (PDF, 131 KB) (PDF, 131 KB) |
| (PDF, 83 KB) (PDF, 220 KB) (PDF, 5.5 MB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
CDC Trioplex Real-time RT-PCR Assay (Trioplex rRT-PCR)
| March 17, 2016 (initial issuance) September 21, 2016 (amended) January 12, 2017 (amended) February 28, 2017 (amended) April 6, 2017 (amended) February 26, 2021 (amended) | (PDF, 82 KB) (PDF, 223 KB) (PDF, 223 KB) (PDF, 223 KB) (PDF, 126 KB) (PDF, 143 KB) |
| (PDF, 224 KB) (PDF, 200 KB) (PDF, 1.45MB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Zika Virus RNA Qualitative Real-Time RT-PCR (Quest Diagnostics Infectious Disease, Inc.) | April 28, 2016 (initial issuance) October 7, 2016 (reissuance) April 11, 2017 (amended) | (PDF, 339 KB) (PDF, 126 KB) |
| (PDF, 53 KB) (PDF, 27 KB) (PDF, 439 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
RealStar Zika Virus RT-PCR Kit U.S. (altona Diagnostics GmbH) | May 13, 2016 (initial issuance) October 31, 2016 (amended) March 6, 2017 (amended) | (PDF, 342 KB) (PDF, 130 KB) (PDF, 130 KB) |
| (PDF, 232 KB) (PDF, 213 KB) (PDF, 809 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Aptima Zika Virus assay (Hologic, Inc.) | June 17, 2016 (initial issuance) September 7, 2016 (amended) April 12, 2017 (amended) March 8, 2018 (amended)
| (PDF, 305 KB) (PDF, 126 KB) (PDF, 124 KB) (PDF, 130 KB)
|
| (PDF, 208 KB) (PDF, 190 KB) (PDF, 276 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Zika Virus Real-time RT-PCR Test (Viracor Eurofins) | July 19, 2016 (initial issuance) February 28, 2017 (amended) | (PDF, 334 KB) (PDF, 124 KB) |
| (PDF, 229 KB) (PDF, 188 KB) (PDF, 623 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
VERSANT Zika RNA 1.0 Assay (kPCR) Kit (Siemens Healthcare Diagnostics Inc.) | July 29, 2016 (initial issuance) December 19, 2016 (amended) | (PDF, 78 KB) (PDF, 124 KB) |
| (PDF, 170 KB) (PDF, 133 KB) (PDF, 511 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Sentosa SA ZIKV RT-PCR Test (Vela Diagnostics USA, Inc.) | September 23, 2016 | (PDF, 355 KB) |
| (PDF, 270 KB) (PDF, 236 KB) (PDF, 1.9 MB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Zika Virus Detection by RT-PCR Test (ARUP Laboratories) | September 28, 2016 | (PDF, 98 KB) |
| (PDF, 52 KB) (PDF, 200 KB) (PDF, 505 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Abbott RealTi e ZIKA (Abbott Molecular Inc.) | November 21, 2016 (initial issuance) January 6, 2017 (amended) | (PDF, 84 KB) (PDF, 150 KB) |
| (PDF, 208 KB) (PDF, 217 KB) (PDF, 1.2 MB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Zika ELITe MGB Kit U.S. (ELITechGroup Inc. Molecular Diagnostics) | December 9, 2016 | (PDF, 312 KB) |
| (PDF, 213 KB) (PDF, 179 KB) (PDF, 718 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
Gene-RADAR Zika Virus Test (Nanobiosym Diagnostics, Inc.) | March 20, 2017 | (PDF, 313 KB) |
| (PDF, 267 KB) (PDF, 240 KB) (PDF, 338 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
TaqPath Zika Virus Kit (Thermo Fisher Scientific) | August 2, 2017 | (PDF, 292 KB) |
| (PDF, 252 KB) (PDF, 180 KB) (PDF, 756 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016)
|
|
CII-ArboViroPlex rRT-PCR Assay (Columbia University) | August 11, 2017 | (PDF, 377 KB) |
| (PDF, 229 KB) (PDF, 176 KB) (PDF, 657 KB) | Diagnostic Tests for Detection of Zika Virus and/or Diagnosis of Zika Virus Infection (February 26, 2016) |
|
IMAGES
VIDEO
COMMENTS
York, Pennsylvania. 771-555-0199. [email protected] May 11, 2023 Dear hiring manager, I'm writing in response to the Secretary job posting I found on the Netterville Design LLC website. As an efficient and organized Secretary with over 10 years of experience working in fast-paced business environments, I believe I have the skills and ...
Here's how to demonstrate these skills in your cover letter: "During my time at XYZ Firm, I was responsible for leading our "Go Green" initiative where we shifted from paper to digital in 85% of work and communication.". Here are important secretary skills to include in your cover letter: 2.
Secretaries are the gatekeepers of an organization, adept at managing information, coordinating tasks, and ensuring seamless communication. Similarly, your cover letter is the gatekeeper of your job application, effectively managing your professional narrative, coordinating your skills and experiences, and ensuring clear communication of your potential. In this guide, we'll delve into the best ...
1. Contact information and salutation. List all essential contact information at the top of your secretary cover letter, including your name, phone number, email, and LinkedIn URL. Greet the hiring manager by name — Mr. or Ms. [Last Name]. If you can't find the hiring manager's name, use a variation of "Dear Hiring Manager.".
Use this Secretary cover letter example to finish your application and get hired fast - no frustration, no guesswork. This cover letter example is specifically designed for Secretary positions in 2024. Take advantage of our sample sentences + expert guides to download the perfect cover letter in just minutes. 4.5.
In this guide we'll cover: Secretary cover letter examples tailored to inspire your writing. A customizable cover letter template designed specifically for secretary roles. Step-by-step guidance on building each section of your cover letter. Additional resources to enhance the impact of your application.
Get started by taking a look at the secretary cover letter example below. Secretary. [ Hiring Manager's name] [Company name] [Company address] [Date] Dear Mr./Ms. [Hiring Manager's Last Name], I am excited to apply for the Secretary position at [Company]. With over 6 years of experience in the field and comprehensive knowledge of office ...
2. Create a Top-Notch Secretary Cover Letter Heading Section. Jot down your name and address at the top left corner of the school or medical secretary cover letter. Next, add the date you're sending the cover letter. Lastly, write the employer's name, their job title, and the company's address details.
Why this cover letter works. One of the prominent qualities of an outstanding legal secretary cover letter is proper formatting. Begin with a strong introduction that showcases your hiring company knowledge, enthusiasm for the role, and relevant job skills.. From there, clearly and concisely detail your professional experiences, emphasizing the skills in legal document preparation and legal ...
Secretary Cover Letter Examples. Cover letters can be difficult, but they don't have to be a daunting task looming over you with every application. To create a polished piece that truly reflects your skills, and to feel confident in your job pursuit, look no further. Our secretary cover letter example and additional do's and don'ts can ...
To make your secretary cover letter stand out from the competition, follow these tips: 1. Start with a strong opening. Your opening sentence should immediately grab the reader's attention and make them want to read more. Consider starting with a personal anecdote, a relevant statistic, or a compelling question. 2.
COVER LETTER. Dear Hiring Manager, In my persistent pursuit to enhance company efficiency and improve client relations, I have meticulously embraced each administrative challenge, galvanizing my aptitude for orchestrating seamless operations within diverse business environments. My tenure at Hessel - Ruecker was marked by a key achievement ...
Secretary Cover Letter Sample. Writing an exceptional secretary cover letter, or secretary application letter, is an important step in the job application process. While not required in many job applications, a strong cover letter can make you stand out against similarly (or more) qualified applicants. ...
Secretaries should include the following elements in their cover letter: 1. Contact Information: Your name, address, phone number, and email address should be at the top of the cover letter. If you're sending an email cover letter, this information can be included in your email signature. 2.
555-555-5555. [email protected]. Retq Group, Inc. Brussels, Belgium. 05/10/2019. Application for the position of Secretary. Dear Hiring Manager, I am writing in response to the job posting on your website seeking an experienced administrative secretary with a strong background in fast-paced business environments.
Here are some key takeaways for writing an impressive Office Secretary cover letter: Focus on the relevant skills and experience you have for the position. Highlight the ways your skills and experience make you the ideal candidate for the Office Secretary job. Demonstrate your communication and organizational skills.
Secretary Cover Letter Example 2. This letter serves as a formal application for the open secretary position within your organization. I would like to thank you for taking the time to review my attached resume. Currently, I am employed in the Enterprise Project Management Office (EPMO) within the IT Division at Thrivent Financial's corporate ...
Cover Letter Body. I am writing to apply for the position of Administrative Secretary. With my strong background in office management, customer service, and administrative support, I am more than qualified to excel in this role. Throughout my career, I have honed my organizational and communication skills.
Here are some key points to keep in mind when crafting a cover letter for this position: Highlight your experience and qualifications that are relevant to the job you're applying for. Show the employer that you have the skills and knowledge they're looking for in a Company Secretary. Demonstrate your knowledge of the company and its objectives.
City, State, Zip Code. Home : 000-000-0000 Cell: 000-000-0000. [email protected]. Dear Mr. Fenton, I am writing to apply for the Assistant Secretary position with Carlton Industries. I am an office management professional with four years of experience as a secretary. In my current position as Assistant Secretary with Alpha Auto I answer telephone ...
A good cover letter for an Admin Secretary job should demonstrate an understanding of the position and how your skills and experience make you the perfect candidate. Showcase your ability to manage complex projects, create solutions to problems, and provide excellent customer service. Demonstrate how your proactive and organized work style ...
The following 2+ cover letter samples for an entry-level secretary resume will assist you in achieving your career goals. Related: Secretary Resume No Experience. Entry-Level New Secretary Cover Letter with No Experience Sample 1. Lisa Simpson 77 Morris Ave Bronx, NY 55343 (000) 989-7665. June 12, 2023. Mr. Abraham Linn
4. Write an attention-grabbing opening paragraph. Start your cover letter with an informative, direct introduction.. In the first one or two sentences, mention the position and organization you're applying for, where you found the position, and why you're excited about the opportunity.
Distinguish your application with our compelling Administrative cover letter examples. Crafted for secretaries, office managers, and administrative professionals, our samples guide you in articulating your organizational prowess and support skills, making you indispensable in the job market.
Cover letters, short or long, are increasingly unpopular among job seekers. However, a 2023 survey of 625 hiring managers across the nation found that 60 percent of companies still require cover letters, writes Rebecca Tay, Ph.D. at ResumeGenius.. While medium and large companies are more likely to require cover letters (72 percent and 69 percent, respectively), nearly half of small businesses ...
Thank you for considering my application. Sincerely, [Full name] [Contact information] 2. Mid-career job application example. You have a wealth of experience under your belt and are ready for a new challenge. This sample letter will help you articulate your accomplishments and how they align with the new role you're seeking:
Sample Application Letter for a Job—First Paragraph Good Example. I am excited to apply for the UX researcher position at Hewlett-Packard. As a UX researcher with over six years of experience in the field, I am confident that my expertise and passion for user-centered design make me an excellent candidate for this role. In my previous ...
Slide 1; Slide 2; Slide 3; Slide 4; Slide 5; Contact information: Ensure your information is professional and up to date. Research shows that only 1 in 10 resumes display portfolios or professional social media profiles, so highlight yours here if you have them.
The HHS Secretary declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to section 564 of the FD&C ...